

FORM 4**UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287

Estimated average burden

hours per response: 0.5

☐ Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Novartis Bioventures Ltd</u> (Last) (First) (Middle) <u>C/O NOVARTIS INTERNATIONAL</u> <u>AG WSJ-200.220</u> (Street) <u>BASEL</u> <u>V8</u> <u>CH-4002</u> (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>Ra Pharmaceuticals, Inc. [RARX]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) <u>02/22/2017</u>	
	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person <input checked="" type="checkbox"/> Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	02/22/2017		S		749	D	\$21.8553 ⁽¹⁾	2,544,903	D ⁽²⁾	
Common Stock	02/23/2017		S		4,999	D	\$21.0362 ⁽¹⁾	2,539,904	D ⁽²⁾	
Common Stock	02/24/2017		S		5,398	D	\$20.9336 ⁽¹⁾	2,534,506	D ⁽²⁾	
Common Stock	02/27/2017		S		57,844	D	\$20.9582 ⁽¹⁾	2,476,662	D ⁽²⁾	
Common Stock	02/28/2017		S		7,847	D	\$20.8577 ⁽¹⁾	2,468,815	D ⁽²⁾	
Common Stock	03/01/2017		S		7,778	D	\$20.9126 ⁽¹⁾	2,461,037	D ⁽²⁾	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V		Date Exercisable	Expiration Date					
						(A) (D)			Title Amount or Number of Shares				

1. Name and Address of Reporting Person* <u>Novartis Bioventures Ltd</u> (Last) (First) (Middle) <u>C/O NOVARTIS INTERNATIONAL</u> <u>AG WSJ-200.220</u> (Street) <u>BASEL</u> <u>V8</u> <u>CH-4002</u> (City) (State) (Zip)		
----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	--	--

1. Name and Address of Reporting Person *

[NOVARTIS AG](#)

(Last) (First) (Middle)

[LICHTSTRASSE 35](#)

(Street)

[BASEL](#)

[V8](#)

[4056](#)

(City)

(State)

(Zip)

Explanation of Responses:

1. Reflects sales of ordinary shares executed in multiple transactions at prices ranging from \$21.85 to \$21.88 on February 22, 2017; \$20.74 to \$21.32 on February 23, 2017; \$20.85 to \$21.01 on February 24, 2017; \$20.85 to \$21.09 on February 27, 2017; \$20.50 to \$21.06 on February 28, 2017; and \$20.50 to \$21.06 on March 1, 2017. The prices reported reflect the weighted average sale prices. The Reporting Persons hereby undertake to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

2. The board of directors of Novartis Bioventures Ltd. has sole voting and investment control and power over such securities. None of the members of its board of directors has individual voting or investment power with respect to such securities and each disclaims beneficial ownership of such securities. Novartis Bioventures Ltd. is an indirectly owned subsidiary of Novartis AG.

Remarks:

[/s/ Simon Zivi, Authorized](#)

[Signatory /s/ Laurieann](#)

[Chaikowsky, Authorized](#)

[Signatory](#)

[05/02/2017](#)

[/s/ Simon Zivi, Authorized](#)

[Signatory /s/ Laurieann](#)

[Chaikowsky, Authorized](#)

[Signatory](#)

[05/02/2017](#)

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.